JPMorgan Downgrades Intra-Cellular Therapies (ITCI) to Neutral
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $34.36 -0.41%
Rating Summary:
15 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 15 | New: 24
Rating Summary:
15 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 15 | New: 24
Trade Now!
Join SI Premium – FREE
JPMorgan analyst Jessica Fye downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Overweight to Neutral with a price target of $26.00 (from $19.00).
For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.
Shares of Intra-Cellular Therapies closed at $22.97 yesterday.
You May Also Be Interested In
- JPMorgan Downgrades Times China Holdings ltd. (1233:HK) (TMPPF) to Neutral
- SCREEN Holdings Co Ltd. (7735:JP) (DINRF) PT Raised to JPY6,600 at Credit Suisse
- Misumi Group (9962:JP) PT Raised to JPY5,400 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
